74936-73-5

Usage

Uses

Used in Pharmaceutical Industry:
BAY-M 5579 is used as an antiviral agent for its ability to inhibit the replication of the hepatitis C virus, providing a potential treatment option for individuals affected by this viral infection.
Used in Enzyme Inhibition:
BAY-M 5579 is used as a protease inhibitor for its inhibitory effects on various proteases, which may have therapeutic applications in treating diseases where protease activity is a contributing factor.
Used in Research and Development:
BAY-M 5579 is used as a research compound to further understand its mechanism of action and explore its potential uses in medical treatments, expanding the knowledge of its applications in various diseases.

Upstream product

• 141-97-9 ethyl acetoacetate 
• 99-61-6 3-nitro-benzaldehyde 
• 626-34-6 ethyl aminocrotonate 
• 102993-38-4 2-cyanoethyl 2-(3-nitrobenzylidene)-3-oxobutanoate 
• 39562-16-8 ethyl 2-(3-nitrophenylmethylene)-3-oxobutanoate 
• 75130-25-5 3-(2-cyanoethyl) 5-ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 

Downstream Products

• 439694-61-8 (R)-5-(ethoxycarbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid 

Relevant academic research and scientific papers

Compound and its as L-type calcium channel blocker or/and application of acetylcholine esterase inhibitors

Disclosed in this invention are compounds and the uses as L-type calcium channel blocker and/or acetylcholinesterase inhibitor thereof. The uses of said compounds in the manufactures of a medicament for the treatment of cardiovascular diseases, apoplexy or senile dementia are also disclosed in the present invention.

Synthesis and characterization of impurities of barnidipine hydrochloride, an antihypertensive drug substance

Barnidipine hydrochloride is a long term dihydropyridine calcium channel blocker used for the treatment of hypertension. During the process development of barnidipine hydrochloride, four barnidipine impurities were detected by high-performance liquid chromatography (HPLC) with an ordinary column (Agilent ZORBAX Eclipse XDB-C18, 150 mm × 4.6 mm, 5 m). All these impurities were identified, synthesized, and subsequently characterized by their respective spectral data (MS, 1H-NMR, and 13C-NMR). The identification of these impurities should be useful for quality control in the manufacture of barnidipine.

1,4-dihydropyridine derivatives

1,4-Dihydropyridine derivatives of formula: STR1 wherein Ar1 represents an aromatic hydrocarbon group or an aromatic heteromonocyclic or heterobicyclic group containing therein 1 to 3 atoms selected from the group consisting of oxygen, sulfur and nitrogen; R1 represents a hydrocarbon group which may have one or more substituents; A represents (i) a straight chain or branched chain unsaturated hydrocarbon group, (ii) a cyclic unsaturated hydrocarbon group, or (iii) a group selected from the group consisting of --R--O--N=CH--, --R--N=N--, --R--CH=N-- and --R--N=CH--, in which R is an alkylene group having 1 to 6 carbon atoms; B represents an alkylene or alkenylene group having 1 to 3 carbon atoms, which may have a substituent; Ar2 represents an aromatic hydrocarbon group or a heterocyclic group; Ar3 represents a heterocyclic group which may have one or more substituents; and n is 0 or 1, and the corresponding optical active 1,4-dihydropyridine derivatives, having an optically active cite as indicated by *, have both superior vasodilative and platelet aggregation inhibiting activities.

Mild and facile cleavage of 2-cyanoethyl ester using sodium sulfide or tetrabutylammonium fluoride. Synthesis of 1,4-dihydropyridine monocarboxylic acids and unsymmetrical 1,4-dihydropyridine dicarboxylates

Several 3-(2-cyanoethyl)-1,4-dihydropyridine carboxylates (16) were prepared in moderate to good yields by means of the Hantzsch reaction. Treatment of these carboxylates with a weak base such as sodium sulfide or tetrabutylammonium fluoride at room temperature afforded smoothly the corresponding 1,4-dihydropyridine monocarboxylic acids (18) in good yields. The monocarboxylic acids 18n and 18o were esterified with 2-nitrooxypropanol or N-(2-hydroxyethyl)nicotinamide p-toluenesulfonic acid salt to afford the selective coronary vasodilators CD-349 (5) and CD-832 (6), respectively.

Synthesis and antihypertensive activities of new 1,4-dihydropyridine derivatives containing a nitrooxy moiety at the 3-ester position

The synthesis of a new series of dihydropyridines containing a nitrooxy moiety at the 3-ester position is described. The antihypertensive activity of the compounds was examined and compared with that of nifedipine; some of them were relatively potent. The structure-activity relationship is also discussed.

Antihypertensive 1,4-dihydropyridines having a conjugated ester

1,4-dihydropyridine derivatives represented by the following general formula, STR1 in which R3 is a combination of an unsaturated straight chain hydrocarbon group or derivative thereof connected by a single bond with an unsaturated hydrocarbon group or derivative thereof so that the unsaturated carbon atoms of the two groups are in conjugated relationship. These compounds have a hypotensive action the effective time of which is long, which makes the blood pressure descend slowly, and the toxicity of which is low.

Process for the preparation of 1,4-dihydropyridinedicarboxylic esters

In the preparation of a 1,4-dihydropyridine of the formula STR1 in which R is a phenyl radical which is optionally substituted once or twice by nitro and/or chlorine, R1 is a C1 -C4 -alkyl radical which is optionally substituted by a C1 -C4 -alkoxy group, and R2 is a C1 -C12 -alkyl radical which is optionally substituted by a C1 -C4 -alkoxy group, a trifluoromethyl group or the radical (C6 H5 CH2) (CH3)N, by preparing an ylidene compound of the formula STR2 and reacting such ylidene compound with an enamine compound of the formula STR3 the improvement which comprises preparing the ylidene compound by reaction of a ketocarboxylic ester of the formula STR4 with an aldehyde of the formula RCHO, in a solvent in the presence of a catalytic amount of any acetate salt of an amine, at a temperature from about -10° C. up to 100° C. The products symmetrical or unsymmetrical, are produced in high yield and purity.